A Study of PRT-201 Administered After Arteriovenous Graft (AVG) Creation in Patients With Chronic Kidney Disease (PRT-201-102)
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of a Single Dose of PRT-201 Administered Immediately After Arteriovenous Graft Creation in Patients With Chronic Kidney Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Fresno, California, United States, 93710
- Ladenheim Dialysis Access Center
-
San Diego, California, United States, 92123
- California Institute of Renal Research
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Washington Hospital/Medstar Research
-
-
Indiana
-
Fort Wayne, Indiana, United States, 46804
- Indiana/Ohio Heart
-
Indianapolis, Indiana, United States, 46202
- Indiana University/Purdue University
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- University of Louisville
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70809
- Vascular Specialty Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham & Women's Hospital
-
Worcester, Massachusetts, United States, 01655
- University of Massachusetts
-
-
New York
-
New York, New York, United States, 10065
- Weill Cornell Medical College
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- University of Cincinnati
-
-
South Carolina
-
Greenville, South Carolina, United States, 29615
- Greenville Memorial Hospital
-
-
Texas
-
Houston, Texas, United States, 77030
- The Methodist Hospital
-
San Antonio, Texas, United States, 78205
- Peripheral Vascular Associates
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Sentara Vascular Specialists
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age of at least 18 years.
- Chronic kidney disease with anticipated start of hemodialysis within 3 months or current hemodialysis dependence.
- Planned creation of a new upper extremity AVG or "jump" graft
Exclusion Criteria:
- Patients for whom this is the only potential site for an upper extremity vascular access.
- Creation of a new AVG or "jump" graft in an upper extremity previously treated with an investigational gene or cell based therapy, or locally with an investigational pharmacological agent.
- On physical examination or by other means, suspected proximal vein stenosis, occlusion, lack of continuity with the subclavian vein, central venous stenosis or central venous occlusion.
- History or presence of an arterial aneurysm.
- Previous treatment with PRT-201.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Applied topically during surgery
|
|
Experimental: PRT-201
|
Applied topically during surgery.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To assess the safety of a single topical dose of PRT-201.
Time Frame: Day of AVG creation and 4 weeks After surgery.
|
Day of AVG creation and 4 weeks After surgery.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Primary graft patency
Time Frame: 3, 6, 9 and 12 months after AVG creation.
|
3, 6, 9 and 12 months after AVG creation.
|
|
Secondary graft patency.
Time Frame: 3, 6, 9 and 12 months after AVG creation.
|
3, 6, 9 and 12 months after AVG creation.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Marco Wong, MD, PhD, Proteon Therapeutics, Inc
Publications and helpful links
General Publications
- Mohamed I, Kamarizan MFA, Da Silva A. Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database Syst Rev. 2021 Jul 23;7(7):CD002786. doi: 10.1002/14651858.CD002786.pub4.
- Dwivedi AJ, Roy-Chaudhury P, Peden EK, Browne BJ, Ladenheim ED, Scavo VA, Gustafson PN, Wong MD, Magill M, Lindow F, Blair AT, Jaff MR, Franano FN, Burke SK. Application of human type I pancreatic elastase (PRT-201) to the venous anastomosis of arteriovenous grafts in patients with chronic kidney disease. J Vasc Access. 2014 Sep-Oct;15(5):376-84. doi: 10.5301/jva.5000235. Epub 2014 May 3.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PRT-201-102
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.